miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery
<div><p>Sense-antisense interactions of long and short RNAs in human cells are integral to post-transcriptional gene regulation, in particular that of mRNAs by microRNAs. Many viruses, including severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 (the causative agent of coronaviru...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513516777504768 |
|---|---|
| author | Tanvir Alam (638619) |
| author2 | Leonard Lipovich (16637) |
| author2_role | author |
| author_facet | Tanvir Alam (638619) Leonard Lipovich (16637) |
| author_role | author |
| dc.creator.none.fl_str_mv | Tanvir Alam (638619) Leonard Lipovich (16637) |
| dc.date.none.fl_str_mv | 2021-03-02T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/ncrna7010018 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/miRCOVID-19_Potential_Targets_of_Human_miRNAs_in_SARS-CoV-2_for_RNA-Based_Drug_Discovery/25756458 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Bioinformatics and computational biology COVID-19 SARS-CoV-2 miR-122 HCV coronavirus microRNA miRNA anti-miR antagomir RNA therapeutics Miravirsen |
| dc.title.none.fl_str_mv | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <div><p>Sense-antisense interactions of long and short RNAs in human cells are integral to post-transcriptional gene regulation, in particular that of mRNAs by microRNAs. Many viruses, including severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 (the causative agent of coronavirus disease 2019, COVID-19), have RNA genomes, and interactions between host and viral RNAs, while known to be functional in other viral diseases, have not yet been investigated in COVID-19. To remedy this gap in knowledge, we present miRCOVID-19, a computational meta-analysis framework identifying the predicted binding sites of human microRNAs along the SARS-CoV-2 RNA genome. To highlight the potential relevance of SARS-CoV-2-genome-complementary miRNAs to COVID-19 pathogenesis, we assessed their expression in COVID-19-relevant tissues using public transcriptome data. miRCOVID-19 identified 14 high-confidence mature miRNAs that are highly likely to interact with the SARS-CoV-2 genome and are expressed in diverse respiratory epithelial and immune cell types that are relevant to COVID-19 pathogenesis. As a proof of principle, we have shown that human miR-122, a previously known co-factor of another RNA virus, the hepatitis C virus (HCV) whose genome it binds as a prerequisite for pathogenesis, was predicted to also bind the SARS-CoV-2 RNA genome with high affinity, suggesting the perspective of repurposing anti-HCV RNA-based drugs, such as Miravirsen, to treat COVID-19. Our study is the first to identify all high-confidence binding sites of human miRNAs in the SARS-CoV-2 genome using multiple tools. Our work directly facilitates experimental validation of the reported targets, which would accelerate RNA-based drug discovery for COVID-19 and has the potential to provide new avenues for treating symptomatic COVID-19, and block SARS-CoV-2 replication, in humans.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Non-Coding RNA<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/ncrna7010018" target="_blank">https://dx.doi.org/10.3390/ncrna7010018</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_e0aacb7fd4dd1040e3bdbeee0cf4e1f9 |
| identifier_str_mv | 10.3390/ncrna7010018 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25756458 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug DiscoveryTanvir Alam (638619)Leonard Lipovich (16637)Biological sciencesBioinformatics and computational biologyCOVID-19SARS-CoV-2miR-122HCVcoronavirusmicroRNAmiRNAanti-miRantagomirRNA therapeuticsMiravirsen<div><p>Sense-antisense interactions of long and short RNAs in human cells are integral to post-transcriptional gene regulation, in particular that of mRNAs by microRNAs. Many viruses, including severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 (the causative agent of coronavirus disease 2019, COVID-19), have RNA genomes, and interactions between host and viral RNAs, while known to be functional in other viral diseases, have not yet been investigated in COVID-19. To remedy this gap in knowledge, we present miRCOVID-19, a computational meta-analysis framework identifying the predicted binding sites of human microRNAs along the SARS-CoV-2 RNA genome. To highlight the potential relevance of SARS-CoV-2-genome-complementary miRNAs to COVID-19 pathogenesis, we assessed their expression in COVID-19-relevant tissues using public transcriptome data. miRCOVID-19 identified 14 high-confidence mature miRNAs that are highly likely to interact with the SARS-CoV-2 genome and are expressed in diverse respiratory epithelial and immune cell types that are relevant to COVID-19 pathogenesis. As a proof of principle, we have shown that human miR-122, a previously known co-factor of another RNA virus, the hepatitis C virus (HCV) whose genome it binds as a prerequisite for pathogenesis, was predicted to also bind the SARS-CoV-2 RNA genome with high affinity, suggesting the perspective of repurposing anti-HCV RNA-based drugs, such as Miravirsen, to treat COVID-19. Our study is the first to identify all high-confidence binding sites of human miRNAs in the SARS-CoV-2 genome using multiple tools. Our work directly facilitates experimental validation of the reported targets, which would accelerate RNA-based drug discovery for COVID-19 and has the potential to provide new avenues for treating symptomatic COVID-19, and block SARS-CoV-2 replication, in humans.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Non-Coding RNA<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/ncrna7010018" target="_blank">https://dx.doi.org/10.3390/ncrna7010018</a></p>2021-03-02T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/ncrna7010018https://figshare.com/articles/journal_contribution/miRCOVID-19_Potential_Targets_of_Human_miRNAs_in_SARS-CoV-2_for_RNA-Based_Drug_Discovery/25756458CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257564582021-03-02T03:00:00Z |
| spellingShingle | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery Tanvir Alam (638619) Biological sciences Bioinformatics and computational biology COVID-19 SARS-CoV-2 miR-122 HCV coronavirus microRNA miRNA anti-miR antagomir RNA therapeutics Miravirsen |
| status_str | publishedVersion |
| title | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery |
| title_full | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery |
| title_fullStr | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery |
| title_full_unstemmed | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery |
| title_short | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery |
| title_sort | miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery |
| topic | Biological sciences Bioinformatics and computational biology COVID-19 SARS-CoV-2 miR-122 HCV coronavirus microRNA miRNA anti-miR antagomir RNA therapeutics Miravirsen |